GRTX Galera Therapeutics
Price Chart
Executive Summary
Galera Therapeutics (GRTX) is merging with private biotech Obsidian Therapeutics in an all-stock transaction, with the combined company to operate as Obsidian Therapeutics (ticker OBX) and supported by a $350 million private placement. Galera shareholders will retain only 1.8% of the combined entity and a contingent right to future milestone payments from a prior asset sale.
Key Financial Metrics
Actionable Insight
Traders should view this as a de facto takeover of Galera by Obsidian, with minimal equity retention for existing GRTX holders. The stock may react negatively due to extreme dilution, even as the $350M financing supports Obsidian’s TIL therapy development. Monitor shareholder approval progress and Nasdaq listing status for OBX.
Key Facts
- Galera is merging with Obsidian Therapeutics in an all-stock deal, with the combined company named Obsidian Therapeutics (OBX).
- Galera shareholders will own only ~1.8% of the combined company post-transaction.
- A $350 million private placement will close prior to the merger, funding operations into 2028.
- Galera shareholders receive a contingent value right (CVR) for 95% of future milestones from its 2025 Biossil.ai asset sale.
- The transaction is expected to close in Q3 2026, subject to shareholder and regulatory approvals.
Financial Impact
Galera shareholders face significant dilution, retaining only 1.8% ownership in the combined company despite the $350M capital raise primarily benefiting Obsidian's pipeline.
Risk Factors
- Extreme dilution for Galera shareholders (down to 1.8%)
- Uncertainty around CVR payout from Biossil.ai deal
- Failure to obtain shareholder or regulatory approvals
- Risk that Obsidian’s OBX-115 fails to meet clinical milestones in 2027
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3273818 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 22, 2026
19d ago
|
425
| $0.1000 $0.1000 | · 0.00% | ▼ −1.66% | $0.0980 (−2.00%) |
|
May 19, 2026
21d ago
|
8-K
| $0.1010 $0.1000 | ▲ +0.99% | ▲ +2.79% | $0.0980 (+2.97%) |
|
Apr 22, 2026
6w ago
|
425
| $0.1000 $0.1000 | · 0.00% | ▼ −0.05% | $0.0980 (−2.00%) |
|
Apr 22, 2026
6w ago
|
425
| $0.1000 $0.1000 | · 0.00% | ▼ −0.05% | $0.0980 (−2.00%) |
|
Apr 14, 2026
8w ago
|
Press Release
| $0.0790 $0.1020 | ▼ −29.11% | ▼ −27.72% | $0.0980 (−24.05%) |
|
Apr 14, 2026
8w ago
|
425
| $0.0790 $0.1020 | ▲ +29.11% | ▲ +27.72% | $0.0980 (+24.05%) |
|
Apr 14, 2026
8w ago
|
8-K
| $0.0790 $0.1020 | ▲ +29.11% | ▲ +27.72% | $0.0980 (+24.05%) |
|
Apr 3, 2026
9w ago
|
8-K
| $0.0410 $0.0420 | ▲ +2.44% | ▼ −1.70% | $0.0980 (+139.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access